MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults

OBJECTIVE: Growth hormone (GH) replacement therapy currently requires daily injections, which may cause distress and low compliance. C-terminal peptide (CTP)-modified growth hormone (MOD-4023) is being developed as a once-weekly dosing regimen in patients with GH deficiency (GHD). This study’s objec...

詳細記述

保存先:
書誌詳細
出版年:Eur J Endocrinol
主要な著者: Strasburger, Christian J, Vanuga, Peter, Payer, Juraj, Pfeifer, Marija, Popovic, Vera, Bajnok, László, Góth, Miklós, Olšovská, Veˇra, Trejbalová, L‘udmila, Vadasz, Janos, Fima, Eyal, Koren, Ronit, Amitzi, Leanne, Bidlingmaier, Martin, Hershkovitz, Oren, Hart, Gili, Biller, Beverly M K
フォーマット: Artigo
言語:Inglês
出版事項: Bioscientifica Ltd 2016
主題:
Clinical Study
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5292974/
https://ncbi.nlm.nih.gov/pubmed/27932411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EJE-16-0748
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料